Definitive Contract 75A50123C00020

This is a $749,000.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to HDT Bio Corp. The contract supports Research and Development (R&D) on the use of HDT Bio's Lion-ReRNA technology in rapid response vaccine development, specifically for an Accelerated Capabilities Initiative (AOI) focused on "Vaccine on Demand." The...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.5 million firm fixed price definitive contract to HDT Bio Corp. to develop an adaptable RNA-based antibody platform for protection against contemporary and emerging human enteroviruses. The three year contract will support HDT Bio Corp.'s work through June 2025 to create a platform that utilizes RNA-based antibodies to provide protection against various...

This is a $408,692 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Univercells SA, a for-profit organization located in Belgium. The contract is for research and development of mRNA vaccine production using Univercells' NFINITYTM platform, under Advance Opportunity Inquiry (AOI) #21 "Vaccine on Demand: R&D for mRNA Production Reinvented." The contract has an ultimate completion date...

This is a $299,959 SBIR Phase I contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company that develops drugs and vaccines for cancer, infectious diseases, and other unmet medical needs. The contract is for research, development, testing, and manufacturing services related to HDT Bio Corp's RNA technologies, adjuvants, antibodies, nanoparticles, and other platforms to create new medical...

This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...

This is a $748,885 firm-fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute based in Seattle, Washington. The contract is for research and development of intranasal administration of RNA vaccines against respiratory pathogens. The contract was awarded under an Ease Broad Agency Announcement (EZ-BAA) issued by the Division of Research, Innovation, and...

This firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Telesis Bio Inc., a for-profit manufacturer, for the provision of a BioXP 3250 system, training, installation, and a case of tips. The total ceiling value of the contract is $99,795.00. The contract was not set aside for any socioeconomic program. The contract is in support of NIAID's Vaccine Production...

This is a $65,806,649.98 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Biofactura Inc. for preclinical and manufacturing development activities. The contract includes cell line development, process development, non-clinical efficacy and safety studies, manufacturing, and clinical activities. The contract was awarded on September 26, 2019 with an ultimate completion date of March 30, 2029. The contract has no...

This is a $1,663,985.13 firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The contract supports the process development and cGMP compliant manufacture of a B19 parvovirus vaccine drug product for use in Phase I/II clinical trials. This contract is part of a larger...

This is a $599,806 firm fixed price definitive contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Pop Biotechnologies Inc., a Buffalo, NY-based small disadvantaged business. The contract is for research and development of "Multivalent QS-18 Protein Nanoparticles for a Broadly Protective Influenza Virus Vaccine" and has a performance period ending on September 29, 2025. The contract...